ET Pharma

Mankind licenses Insulin Degludec and Aspart combo from China’s Chenan Bio

Aug 20, 2026, 8:13 AM

Translate article text

Choose a language and wait for the translated text.

The licensed drugs are alternatives to Novo Nordisk’s Tresiba and Ryzodeg. Both biosimilar therapies have completed their Phase 3 studies in China.